Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10367950" target="_blank" >RIV/00216208:11110/18:10367950 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00102719 RIV/00209805:_____/18:00077997 RIV/00216208:11130/18:10367950 RIV/00216208:11140/18:10367950 a 6 dalších

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.12243" target="_blank" >http://dx.doi.org/10.21873/anticanres.12243</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12243" target="_blank" >10.21873/anticanres.12243</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Popis výsledku v původním jazyce

Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Název v anglickém jazyce

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Popis výsledku anglicky

Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

449-456

Kód UT WoS článku

000419130100060

EID výsledku v databázi Scopus

2-s2.0-85039776678